{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:13:02Z","timestamp":1777914782248,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Steatotic liver disease (SLD), largely driven by cardiometabolic dysfunction, affects nearly one-third of the global population and may progress to advanced fibrosis. Although liver biopsy remains the gold standard for fibrosis assessment, noninvasive tools such as the Fibrosis-4 (FIB-4) and the recently developed steatosis-associated fibrosis estimator (SAFE) score are used risk stratification. We compared the diagnostic accuracy of FIB-4 and SAFE for detecting clinically significant fibrosis in adults with cardiometabolic risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of 2196 adults aged 18\u201380 years from the National Health and Nutrition Examination Survey (2017\u20132020) with valid liver stiffness measurements (LSM) by FibroScan. Individuals with known chronic liver disease, excessive alcohol use, or missing data were excluded. Clinically significant fibrosis was defined as LSM \u2265 8.0 kPa. Diagnostic performance was evaluated using sensitivity, specificity, predictive values, and area under the receiver operating characteristic curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SAFE demonstrated superior discrimination compared with FIB-4 (AUC 0.719 vs. 0.578;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). As a rule-out test, SAFE showed higher sensitivity (78% vs. 41%) and negative predictive value (95% vs. 91%). FIB-4 missed 58.6% of patients with significant fibrosis, whereas SAFE missed 22%. SAFE consistently outperformed FIB-4 across age, sex, MASLD status, and glycemic control subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings support the use of SAFE over FIB-4 as a noninvasive screening tool for significant fibrosis in patients with cardiometabolic risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/meg.0000000000003161","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:00:38Z","timestamp":1772722838000},"page":"738-746","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["SAFE vs. FIB-4: diagnostic accuracy for clinically significant fibrosis in U.S. adults with cardiometabolic risk factors \u2013 a NHANES 2017\u20132020 analysis"],"prefix":"10.1097","volume":"38","author":[{"given":"Adem","family":"Aydin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Saint Mary\u2019s Hospital, Waterbury, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucel","family":"Aydin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tulane University, New Orleans, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina I.","family":"Borz-Baba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Mary\u2019s Hospital, Waterbury, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"R1-20260501","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20260501","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.amjmed.2020.08.010","article-title":"The impact of nonalcoholic fatty liver disease in primary care: a population health perspective.","volume":"134","author":"Dokmak","year":"2021","journal-title":"Am J Med"},{"key":"R3-20260501","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R4-20260501","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1053\/j.gastro.2011.02.058","article-title":"Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.","volume":"140","author":"Vergniol","year":"2011","journal-title":"Gastroenterology"},{"key":"R5-20260501","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1053\/j.gastro.2017.03.017","article-title":"American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of liver fibrosis.","volume":"152","author":"Lim","year":"2017","journal-title":"Gastroenterology"},{"key":"R6-20260501","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R7-20260501","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R8-20260501","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis\u2010associated fibrosis estimator (SAFE) score: a tool to detect low\u2010risk NAFLD in primary care.","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology"},{"key":"R9-20260501","doi-asserted-by":"crossref","first-page":"e0075","DOI":"10.1097\/HC9.0000000000000075","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population.","volume":"7","author":"van Kleef","year":"2023","journal-title":"Hepatol Commun"},{"key":"R10-20260501","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"R11-20260501","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"R14-20260501","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02295996","article-title":"Note on the sampling error of the difference between correlated proportions or percentages.","volume":"12","author":"McNemar","year":"1947","journal-title":"Psychometrika"},{"key":"R15-20260501","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R16-20260501","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"R17-20260501","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease.","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"R18-20260501","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review.","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"R19-20260501","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review.","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"R20-20260501","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"key":"R21-20260501","first-page":"e0609","article-title":"Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care.","volume":"9","author":"Sung","year":"2024","journal-title":"Hepatol Commun"},{"key":"R22-20260501","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R23-20260501","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R24-20260501","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","article-title":"Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications.","volume":"21","author":"Boursier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-20260501","doi-asserted-by":"crossref","first-page":"e40214","DOI":"10.1097\/MD.0000000000040214","article-title":"Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring.","volume":"103","author":"Chen","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"R26-20260501","first-page":"S61","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142026.","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"R27-20260501","doi-asserted-by":"crossref","first-page":"24772","DOI":"10.1038\/s41598-025-10871-9","article-title":"MISHTI study evaluating hepatic fibrosis in type 2 diabetes patients in India.","volume":"15","author":"Datta","year":"2025","journal-title":"Sci Rep"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000003161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:01:21Z","timestamp":1777654881000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000003161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000003161","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2025-06-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}